Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

This study found that GnRH-a treatment or orchiectomy, which required significantly lower doses of oral estradiol valerate, were more effective than anti-androgens like spironolactone and finasteride in achieving target hormone levels in transgender females in India.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

Isoflavones may help with menopause symptoms but could be risky for women with hormone-sensitive cancers.

This literature review suggests that herbal extracts show promise as antiandrogenic agents for androgen-related conditions, potentially offering a natural alternative with fewer side effects than synthetic medications.

This article states that hormone therapy with estrogens and antiandrogens for transgender females is within an obstetrician-gynecologist's practice scope and involves careful dosing and monitoring to manage short-term thrombotic risks.

This meta-analysis found that while both Dienogest and GnRH analogues effectively managed endometriosis-related pain, Dienogest reduced recurrence rates and hot flushes but increased irregular bleeding, making it a safer option due to fewer side effects.

In this study, finasteride inhibited progesterone synthesis in mouse-derived MA-10 Leydig tumor cells by blocking cholesterol side-chain cleavage, but human and rat cells showed minimal sensitivity.

This review explores plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, for their potential use as alternative treatments for prostate cancer, emphasizing their effects on 5-alpha-Reductase enzyme isozymes. It reports no new clinical results.

This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.

This study found that progesterone can inhibit spinal reflex potentiation in ovariectomized rats through GABA(A) receptor activity, mediated by neurosteroid metabolism rather than direct progesterone receptor action.

In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.

The researchers reported that metabolism of progesterone to 3α,5α-THP in the hippocampus is important for its antiseizure effects in ovariectomized rats.

This review suggests that estroprogestins with anti-androgenic progestins, like cyproterone acetate and drospirenone, may effectively manage androgen excess in PCOS women, considering individual patient profiles.

This article suggests using oral contraceptives with antiandrogenic properties for women with virilization symptoms like acne and advises higher doses of antiandrogens for severe acne, androgenic alopecia, or idiopathic hirsutism.

This study found that several preservatives, including triclocarban and triclosan, showed potential endocrine-disrupting effects on various nuclear receptors in both in silico and in vitro models.

This study concluded that mixtures of weak endocrine disruptors, such as parabens and azole fungicides, can produce combination effects that should be considered in regulatory risk assessments to avoid underestimating potential risks.

This study found that cyproterone acetate with ethynyl estradiol improved acne and seborrhea within 3–6 months in women, but had less satisfactory results for alopecia and hirsutism.

This study synthesized new heterocyclic steroid derivatives and reported their promising antiproliferative activity against breast and prostate cancer cell lines, highlighting selectivity and impact on signaling pathways even in cells resistant to certain treatments.

Androstenedione, a hormone supplement, doesn't improve muscle or performance and can cause harmful side effects.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This article discusses the mechanisms and therapeutic use of antiandrogens, specifically cyproterone acetate and chlormadinone acetate, in gynecological treatments without reporting new clinical results.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

This review discusses the role of androgens in the progression of cardiovascular disease and explores novel therapeutic targets without reporting new clinical results.

This review details the expression and diverse functions of melatonin receptors in non-neural tissues and reports no new clinical findings, emphasizing their potential as therapeutic targets across various physiological and pathological processes.

This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.

This study found that sorafenib was active against desmoid tumors, with 25% of patients achieving a partial response and 70% maintaining stable disease.